Please login to the form below

Not currently logged in
Email:
Password:

Sun Pharma passes milestone with novel psoriasis drug approval

Ilumya will treat adults with a moderate-to-severe form of the skin condition

Sun Pharma

India’s largest drugmaker Sun Pharmaceutical has picked up its first FDA approval for a novel drug, getting the nod for plaque psoriasis therapy Ilumya.

The US regulator has approved Ilumya (tildrakizumab-asmn) for adults with moderate-to-severe psoriasis on the back of clinical trial data comparing the drug against placebo and Amgen’s TNF inhibitor Enbrel (etanercept), a widely-used biologic for the skin condition.

Ilumya isn’t entirely home-grown, as Sun Pharma licensed the interleukin-23 (IL-23) inhibitor for Merck & Co/MSD in 2014, but the green light is a landmark along the Indian company’s journey from being primarily a producer of generic medicines.

The company may find the going tough once it starts commercialising the drug however, as psoriasis therapy has seen a big increase in the number of drugs competing for market share of late. For years treatment for patients requiring systemic therapy has been dominated by TNF blockers such as Enbrel and AbbVie’s Humira (adalimumab), but these are now expected to lose market share to new entrants, and particularly selective interleukin inhibitors, thanks largely to improved tolerability.

Johnson & Johnson's IL-12/IL-23 blocker Stelara (ustekinumab) was the first interleukin drug to reach the market and swiftly reached blockbuster sales level, and has since been joined by IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

Meanwhile, AbbVie has an IL-23 blocker called risankizumab in late-stage testing that it thinks could be a best-in-class treatment and a $1bn-plus contender in psoriasis. With competition heating up - particularly in patients who have already been treated with TNF blockers - analysts have predicted that Ilumya is likely to be a modest product in psoriasis with sales estimates well below $500m a year.

“With the approval of Ilumya and our long-standing commitment in dermatology, we are focused on making a difference for people living with moderate-to-severe plaque psoriasis,” said Sun Pharma’s US president and chief executive Abhay Gandhi.

“We are committed to working with all relevant stakeholders to make Ilumya available to appropriate people with plaque psoriasis,” he added.

Last November, Sun Pharma’s European licensee for tildrakizumab - Spain’s Almirall - said it expects the launch of the drug in the EU to be delayed by at least six months because of regulatory issues. It’s now hoping to make it available around the end of this year or early in 2019.

Almirall licensed European rights to the drug in July 2016 and filed for the regulatory approval with the EMA in March 2017.

Article by
Phil Taylor

22nd March 2018

From: Regulatory

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics